These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17622393)

  • 1. Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.
    LeLorier J; Rawson NS
    Can J Cardiol; 2007 Jul; 23(9):711-8. PubMed ID: 17622393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand.
    Rawson NSB
    Front Public Health; 2020; 8():544835. PubMed ID: 33194946
    [No Abstract]   [Full Text] [Related]  

  • 3. Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
    Tu JV
    Can J Cardiol; 2007 Jul; 23(9):719-20. PubMed ID: 17622394
    [No Abstract]   [Full Text] [Related]  

  • 4. Indigenous disparities in disease-specific mortality, a cross-country comparison: New Zealand, Australia, Canada, and the United States.
    Bramley D; Hebert P; Jackson R; Chassin M
    N Z Med J; 2004 Dec; 117(1207):U1215. PubMed ID: 15608808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular mortality in New Zealand and Australia 1968-1983: how can the diverging trends be explained?
    Beaglehole R; Bonita R; Jackson R; Stewart A
    N Z Med J; 1986 Jan; 99(794):1-3. PubMed ID: 3456096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a health literacy intervention trial on knowledge about cardiovascular disease medications among Indigenous peoples in Australia, Canada and New Zealand.
    Crengle S; Luke JN; Lambert M; Smylie JK; Reid S; Harré-Hindmarsh J; Kelaher M
    BMJ Open; 2018 Jan; 8(1):e018569. PubMed ID: 29371275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.
    Stewart RA; North FM; Sharples KJ; Simes RJ; Tonkin AM; White HD;
    N Z Med J; 2008 Feb; 121(1269):11-23. PubMed ID: 18278078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the burden of fatal drowning and data characteristics in three high income countries: Australia, Canada and New Zealand.
    Peden AE; Franklin RC; Clemens T
    BMC Public Health; 2019 Jun; 19(1):794. PubMed ID: 31226973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness, cost effectiveness, acceptability and implementation barriers/enablers of chronic kidney disease management programs for Indigenous people in Australia, New Zealand and Canada: a systematic review of mixed evidence.
    Reilly R; Evans K; Gomersall J; Gorham G; Peters MD; Warren S; O'Shea R; Cass A; Brown A
    BMC Health Serv Res; 2016 Apr; 16():119. PubMed ID: 27048280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
    Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063
    [No Abstract]   [Full Text] [Related]  

  • 12. Why do Australians live longer than New Zealanders?
    O'Donoghue B; Howden-Chapman P; Woodward A
    Health Educ Behav; 2000 Jun; 27(3):307-16. PubMed ID: 10834804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational use of medications: if Canada can't do it ..
    Califf RM
    CMAJ; 2009 Jul; 181(1-2):15-6. PubMed ID: 19581612
    [No Abstract]   [Full Text] [Related]  

  • 16. Health policy responses to rising rates of multi-morbid chronic illness in Australia and New Zealand.
    Aspin C; Jowsey T; Glasgow N; Dugdale P; Nolte E; O'Hallahan J; Leeder S
    Aust N Z J Public Health; 2010 Aug; 34(4):386-93. PubMed ID: 20649779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand.
    Coriati A; Ma X; Sykes J; Stanojevic S; Ruseckaite R; Lemonnier L; Dehillotte C; Tate J; Byrnes CA; Bell SC; Burgel PR; Stephenson AL
    Thorax; 2023 Mar; 78(3):242-248. PubMed ID: 36109163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and length-of-stay outcomes, 1993-2003, in the binational Australian and New Zealand intensive care adult patient database.
    Moran JL; Bristow P; Solomon PJ; George C; Hart GK;
    Crit Care Med; 2008 Jan; 36(1):46-61. PubMed ID: 18090383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of studies of quality of clinical care in general practice in the UK, Australia and New Zealand.
    Seddon ME; Marshall MN; Campbell SM; Roland MO
    Qual Health Care; 2001 Sep; 10(3):152-8. PubMed ID: 11533422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality trends in Australian Aboriginal peoples and New Zealand Māori.
    Phillips B; Daniels J; Woodward A; Blakely T; Taylor R; Morrell S
    Popul Health Metr; 2017; 15():25. PubMed ID: 28680369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.